We want to switch to serum-free medium for avian cell culture. Are there batches suitable for veterinary vaccine R&D?

Serum-free adaptation differs between CEF and DF-1. DF-1 is relatively easy to adapt; you can ask distributors for trial samples of serum-free or low-serum medium. CEF are primary cells with high serum dependence, so it is advisable to start with low serum (e.g., 2% replacing 10%) or "partial replacement" rather than removing serum all at once. Trial samples are generally tens to hundreds of milliliters, enough for you to run 2-3 replicates in a dozen or so flasks. When applying, state directly that you are doing poultry vaccine R&D; manufacturers will usually require signing a simple trial agreement. For imported options such as Gibco, Lonza, and Sigma custom or poultry-specific formulations, lead times may be 4-8 weeks, while domestic brands such as ExCell Bio, Yuanpei, and OPM Biosciences are faster, with in-stock or rapid formulations in 1-2 weeks. First shortlist 2-3 candidates, use the same batch of CEF and DF-1 for comparison, and check attachment, morphology, and doubling.

From a supply chain and scale-up perspective, free trial samples are available from many manufacturers, but note that a "small trial" may only be 100-500 ml, enough for you to run one to two rounds with a dozen or so flasks. Imported avian serum-free media have long lead times, some requiring 4-6 weeks or even longer, while domestic ones generally take 1-2 weeks; if you are in a hurry, you can first ask the distributor to send the same-series basal medium as a control. Pilot-scale pricing is usually not purchased directly at catalog small-package prices; it is recommended to sign a pilot trial production agreement, quote based on batch or annual usage, and clarify the minimum order quantity, supply cycle, and whether quality control documents can meet veterinary vaccine R&D requirements. For serum-free media involving recombinant proteins or hydrolysates, the source and batch-to-batch variation are equally critical; you can request the manufacturer to provide three batches of COA or small samples for batch-to-batch validation. For CEF, it is recommended to focus on media for primary isolation; for DF-1, commercial low-serum media can be selected.

It is recommended to screen culture media through "serum-reduced adaptation" rather than direct replacement. Use the current system as a control, and divide candidate low-serum/serum-free media into gradients: 10% to 5%, 2%, and serum-free, with continuous passage for 2-3 generations, recording cell viability, confluence time, and TCID50 or fluorescence quantification after virus amplification. If CEF primary cells do not plate well, additional adherence factors or extracellular matrix coating may be needed, and the cost should be included. Trial samples can be requested from 2-3 vendors simultaneously, and each vendor should be asked clearly whether the product contains animal-derived components and whether it is suitable for veterinary biological product development. During pilot scale-up, pricing is generally re-quoted based on packaging specifications and annual purchase volume, which is completely different from buying a few bottles at small-scale; tiered pricing can be negotiated commercially. However, do not compare only the price per liter; also consider ease of media preparation and batch-to-batch stability.